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Abstract
A striking and clinically relevant virulence trait of the human fungal pathogen Candida albicans is its ability to grow and
switch reversibly among different morphological forms. Inhibition of yeast-to-hypha transition in C. albicans represents
a new paradigm for antifungal intervention. We have previously demonstrated the novel antifungal activity of purpurin
against Candida fungi. In this study, we extended our investigation by examining the in vitro effect of purpurin on C.
albicans morphogenesis and biofilms. The susceptibility of C. albicans biofilms to purpurin was examined quantitatively by
2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-carboxanilide reduction assay. Hyphal formation and biofilm
ultrastructure were examined qualitatively by scanning electron microscopy (SEM). Quantitative reverse transcription-PCR
(qRT-PCR) was used to evaluate the expression of hypha-specific genes and hyphal regulator in purpurin-treated fungal
cells. The results showed that, at sub-lethal concentration (3 mg/ml), purpurin blocked the yeast-to-hypha transition under
hypha-inducing conditions. Purpurin also inhibited C. albicans biofilm formation and reduced the metabolic activity of
mature biofilms in a concentration-dependent manner. SEM images showed that purpurin-treated C. albicans biofilms were
scanty and exclusively consisted of aggregates of blastospores. qRT-PCR analyses indicated that purpurin downregulated
the expression of hypha-specific genes (ALS3, ECE1, HWP1, HYR1) and the hyphal regulator RAS1. The data strongly
suggested that purpurin suppressed C. albicans morphogenesis and caused distorted biofilm formation. By virtue of the
ability to block these two virulence traits in C. albicans, purpurin may represent a potential candidate that deserves further
investigations in the development of antifungal strategies against this notorious human fungal pathogen in vivo.
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Introduction
Candida albicans is a prevalent human fungal pathogen that poses
significant medical challenge. It exists as a benign commensal in
immunocompetent individuals but can become invasive and cause
infections when the host immunity is impaired [1]. Recurrent
lesions are not fatal; however, disseminated mycoses can be lethal
with high morbidity and mortality (,40–60%) [2]. In fact,
candidiasis has been ranked fourth among leading types of
nosocomial infections [3,4]. The limited arsenal of conventional
antifungal treatments for candidiasis relies heavily on polyenes,
azoles and echinocandins. Unfortunately, they either have narrow
therapeutic index, poor bioavailability, poor gastrointestinal
absorption, or severe side effects [5,6]. In addition, overuse of
antifungal agents often leads to emergence of resistant strains that
complicates the management of fungal infections in clinical
settings [7].
The ability of C. albicans to colonize and proliferate in humans is
closely related to its pathogenicity. One striking virulence trait of
C. albicans is its ability to survive and switch reversibly between
budded yeast and filamentous forms (pseudohyphae, true hyphae)
[8,9]. The phenotypic plasticity is tightly regulated by environ-
mental cues. Cells grown in the presence of serum, or at high
temperature (37uC), or under neutral/alkaline conditions, trigger
hyphal formation [10]. The yeast-to-hypha transition is crucial for
C. albicans infectivity. It is governed by the intracellular signalling
pathways, for example, the cyclic AMP-protein kinase A (cAMP-
PKA) and the Cek1 mitogen-activated protein kinase (MAPK)
pathways which are tightly modulated by the membrane-bound
GTPase (Ras1p) [11,12]. Blockade of hyphal growth attenuates
host’s tissue damage, and mutants defective in filamentation or
locked in the yeast form are avirulent in systemic candidiasis
[13,14]. Hyphae not only help C. albicans to escape from host
defence, but are also essential for pathogenicity by forming
biofilms - heterogenous sessile communities of yeast and hyphal
cells encased in extracellular matrix [15,16]. Candida biofilms are
highly resistant to standard antifungal treatments. Biofilms on
various indwelling implanted devices, such as vascular/urinary
catheters and denture, are excellent reservoirs to persistent fungal
infections. It has been estimated that 80% of infections are biofilm-
associated [17]. Therefore, impairment of hyphal development
and biofilms may represent an effective and tangible measure to
alleviate C. albicans pathogenesis, in line with the current antifungal
paradigm that targets virulence traits instead of microbial
eradication [18].
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Purpurin (1,2,4-trihydroxy-9,10-anthraquinone) is a natural red
anthraquinone pigment commonly found in madder root (Rubia
tinctorum L.). It is an ingredient of herbal medicine and has been
widely used as a food colouring agent [19]. We recently
demonstrated the potent in vitro antifungal activity of purpurin
against six Candida species [20]. Considering the repression of
yeast-to-hypha transition attenuates C. albicans virulence/patho-
genesis, the present study was designed to investigate the in vitro
effect of purpurin on biofilms and hyphal development.
Methods
Strains, Cultivation and Chemicals
Wild type C. albicans strain SC5314 was routinely cultured in
YPD agar (1% yeast extract, 2% peptone, 2% dextrose, 2% agar)
at 30uC. To prepare a standard cell suspension, a single colony
was inoculated into YNB medium (0.67% yeast nitrogen base w/o
amino acids, 2% dextrose) and incubated for 18 h at 30uC with
agitation. The fungal cells were harvested by centrifugation,
washed twice in PBS (pH 7.2), and resuspended at 16107 cells/ml.
Spider medium [21] and RPMI medium were used for hyphal
induction at 37uC. Purpurin was purchased from TimTec Inc.
(Newark, DE, USA). Stock solution (5 mg/ml) was prepared by
dissolution in distilled dimethyl sulphoxide (DMSO) and kept at
220uC until use. The final concentration of DMSO was 1% in all
assays. Other general chemicals were obtained from commercial
suppliers with the highest grade available.
Effect of Purpurin on C. albicans Biofilm Formation and
Pre-formed Biofilms
Fungal biofilms were prepared as described [22] on commer-
cially available, pre-sterilized, flat-bottomed 96-well polystyrene
microtitre plates (Iwaki). Standard cell suspension of C. albicans
(100 ml) was transferred into the wells and incubated for 1.5 h at
37uC with agitation. After the adhesion phase, the liquid was
aspirated and each well was washed twice with PBS to remove
loosely attached cells. Fresh YNB medium (200 ml) containing
different concentrations (1 mg/ml to 10 mg/ml) of purpurin were
added to each well and the plate was further incubated for 24 h at
37uC.
To investigate the effect of purpurin on pre-formed biofilms, C.
albicans biofilms were prepared for 24 h at 37uC as described
above. The wells were washed twice with PBS and fresh YNB
medium (200 ml) containing different concentrations (1 mg/ml to
10 mg/ml) of purpurin were added and the plate was further
incubated for 24 h at 37uC. YNB medium with 1% DMSO was
included in control wells. The metabolic activity of the C. albicans
biofilms was determined quantitatively using a standard 2,3-bis(2-
methoxy-4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-carboxanilide
(XTT) reduction assay.
Quantitative Analysis - XTT Reduction Assay
At the end of the incubation, the supernatant was aspirated and
the wells were washed twice with PBS. The fungal cell viability was
determined using colorimetric XTT reduction assay that measures
the activity of mitochondrial dehydrogenase [23]. XTT solution
(1 mg/ml) was prepared by dissolving XTT powder in PBS, and
the solution was filter-sterilized (0.22 mm pore size filter). XTT
solution (40 ml) was mixed with freshly prepared menadione
solution (0.4 mM; 2 ml) at 20:1 (v/v) immediately prior to the
assay. Thereafter, PBS (158 ml) was mixed with XTT-menadione
solution (42 ml) and transferred to each well containing pre-washed
biofilms, and incubated in the dark for 3 h at 37uC. After the
incubation, the coloured supernatant (100 ml) was transferred to
new microtiter plates, and the optical density of the supernatant
was measured at 492 nm with a microtitre plate reader
(SpectraMax 340 tunable microplate reader; Molecular Devices).
Qualitative Analysis - Scanning Electron Microscopy
C. albicans biofilms were prepared on custom-made, tissue
culture-treated, polystyrene coverslips as described [22]. Thereaf-
ter, the coverslips were washed twice with PBS and placed in 1%
osmium tetroxide for 1 h. Samples were subsequently washed with
distilled water, dehydrated in a series of ethanol solutions (70% for
10 min, 95% for 10 min and 100% for 20 min), and air-dried
overnight in a desiccator prior to sputter coating with gold (JFC1
100; JEOL). The surface topographies of the C. albicans biofilms
were viewed with a scanning electron microscope (Philip
XL30CP).
Effect of Purpurin on C. albicans Hyphal Growth on Solid
Media
Standard cell suspension of C. albicans was spread on Spider
plates or on YPD plates containing 10% fetal bovine serum (FBS)
(Invitrogen) supplemented with DMSO or different concentrations
(1 mg/ml to 5 mg/ml) of purpurin. The plates were incubated for 4
days at 37uC and the morphology of fungal colony was
photographed using a digital camera.
Effect of Purpurin on C. albicans Hyphal Growth in Liquid
Media
Standard cell suspension of C. albicans was diluted (at 16106
cells/ml) in Spider medium or YPD medium containing 10% FBS
or RPMI medium containing 10% FBS supplemented with
DMSO or different concentrations (1 mg/ml to 5 mg/ml) of
purpurin. Cells were grown at 37uC with agitation (250 rpm) for
4 h. Aliquots of fungal cells were visualized by differential
interference contrast (DIC) microscopy and photographed.
Evaluation of Purpurin Cytotoxicity
Primary human gingival fibroblasts (HGFs) were obtained from
ScienCell Research Laboratories (Carlsbad, CA, USA). The cells
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)
(Sigma) supplemented with 10% foetal bovine serum, penicillin
(1 IU/ml), streptomycin (1 mg/ml) and L-glutamine (200 mM) in
a humidified incubator at 37uC with 5% CO2 until 80% confluent.
HGFs were subcultured by trypsinisation and cells of third passage
were used. For cytotoxicity assay, HGFs (26104 cells; 100 ml) were
seeded in 96-well microtitre plates for 24 h, followed by addition
of different concentrations (0.1 mg/ml to 10 mg/ml) of purpurin in
growth medium (100 ml). Cell viability was determined by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT)
assay after 24 h. MTT solution (5 mg/ml) was prepared by
dissolving MTT powder in PBS, and the solution was filter-
sterilized (0.22 mm pore size filter) to remove insoluble residue. At
the end of the incubation, the supernatant was aspirated and MTT
solution (20 ml) was added to each well and incubated for 4 h at
37uC. The solution was replaced by DMSO (1 ml) to dissolve the
dark blue formazan crystals. After incubation for 15 min at room
temperature, the absorbance was read in microtitre plate reader at
570 nm.
qRT-PCR Analysis of C. albicans Hypha-specific Genes and
the Hyphal Regulator RAS1
Standard cell suspension of C. albicans (1 ml) was transferred into
the wells of a pre-sterilized, flat-bottomed 24-well polystyrene
microtiter plates (Iwaki). After incubation for 1.5 h at 37uC with
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agitation, the liquid was aspirated and each well was washed twice
with PBS. Fresh YNB medium (1 ml) containing 3 mg/ml of
purpurin was added to each well and the plate was further
incubated for 24 h at 37uC. Control wells without the addition of
purpurin were included for comparison. At the end of the
incubation, the supernatant was aspirated and the wells were
washed twice with PBS. Total RNA was extracted from C. albicans
biofilms using SV Total RNA Isolation System (Promega) and
2 mg of template was reverse transcribed with Superscript II
(Invitrogen). Resultant cDNAs were amplified by PCR and
product specificity was confirmed by sequencing.
Real time PCR primers were designed for C. albicans hypha-
specific genes (ALS3, ECE1, HWP1, HYR1), and the hyphal
regulator RAS1 using Primer Express Software Version 3 (Applied
Biosystems) (Table 1). Primers were designed to generate
amplicons with sizes between 50–150 bp and Tm between 58–
60uC. Real time PCR mixture (20 ml) contained 10 ml of Fast
SYBR Green Master Mix, 1 ml each of primers and 8 ml of sterile
MilliQ water. The reactions were run on Step One Real time PCR
Systems (Version 2, Applied Biosystems) (95uC incubation for 20 s,
followed by 40 cycles of 95uC incubation for 1 s and 60uC for
20 s). Each primer pair produced a single amplicon with a uniform
melting curve. A standard curve was constructed with a series of
purified PCR products and the absolute copy number of
amplicons was quantified (amplification efficiency .90%,
R2.0.970). EFB1 was used as a house keeping gene for reference
(Table 1) [24–26].
Statistical Analysis
All experiments were performed in triplicate in three different
occasions. All data were expressed as mean values with the
corresponding standard deviations (SD). Differences between
treated and control groups were assessed by Student’s t test or
Mann-Whitney U test. In both tests, a p-value of ,0.01 was
considered statistically significant.
Results
Effect of Purpurin on C. albicans Biofilms
The antifungal activity of purpurin on C. albicans biofilms was
evaluated quantitatively using the XTT reduction assay. The
effect was concentration-dependent, as reflected by a progressive
reduction in cell viability, represented by metabolic activity, with
increasing concentrations of purpurin (Fig. 1A). The metabolic
activity of C. albicans during biofilm formation was reduced by
,44% at 3 mg/ml and by ,64% at 10 mg/ml. Pre-formed
(mature) C. albicans biofilms were more resistant to the antifungal
activity of purpurin, as revealed by a modest reduction in the cell
viability by ,6% at 3 mg/ml and by ,37% at 10 mg/ml (Fig. 1B).
SEM images showed that purpurin significantly suppressed C.
albicans biofilm formation, C. albicans biofilms that were treated
with purpurin were devoid of hyphal growth, scanty and
exclusively consisted of aggregates of blastospores (Figs. 2A-D).
Table 1. Primers used for qRT-PCR.
Primer Sequence (59–39)
ALS3f CTGGACCACCAGGAAACACT
ALS3r ACCTGGAGGAGCAGTGAAAG
ECE1f GTCGTCAGATTGCCAGAAATTG
ECE1r CTTGGCATTTTCGATGGATTGT
HWP1f GCCCAGAAAGTTCTGTTCCA
HWP1r TTTGGTTTCAGTAGTAGTGGTTGG
HYR1f TTGTTTGCGTCATCAAGACTTTG
HYR1r GTCTTCATCAGCAGTAACACAACCA
RAS1f CCCAACTATTGAGGATTCTTATCGTAAA
RAS1r TCTCATGGCCAGATATTCTTCTTG
EFB1f CATTGATGGTACTACTGCCAC
EFB1r TTTACCGGCTGGCAAGTCTT
doi:10.1371/journal.pone.0050866.t001
Figure 1. Effect of purpurin on Candida albicans biofilms. A)
Biofilm formation of C. albicans SC5314 was examined in YNB medium
containing the indicated concentrations of purpurin for 24 h at 37uC. B)
Purpurin was added to pre-formed (mature) C. albicans biofilms and
incubated in YNB medium for an additional 24 h at 37uC. The metabolic
activity of the biofilms was assessed quantitatively using XTT reduction
assay. The activity of samples without purpurin treatment (i.e. DMSO
only) (0 mg/ml) was taken as 100%. Results shown were the average of
three independent experiments 6 SD. *p,0.01 when compared with
the untreated controls.
doi:10.1371/journal.pone.0050866.g001
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Effect of Purpurin on C. albicans Hyphal Growth
We examined the effect of purpurin on C. albicans hyphal growth
on solid media by cultivating fungal cells and observing colony
morphology on Spider agar at 37uC and on YPD agar containing
10% FBS (hypha-inducing conditions) supplemented with different
concentrations of purpurin. It was found that 3 mg/ml of purpurin
was sufficient to abrogate filamentation (Figs. 3A and B).
Microscopic observation of the purpurin-treated fungal cells
revealed an absence of filamentous cells whereas the control
colony contained massive filamentation under both hypha-
inducing conditions (data not shown). We also examined the
effect of purpurin on hyphal growth in three different liquid media
at 37uC. In both Spider medium and YPD medium containing
10% FBS, fungal cells grew as budding yeast form in the presence
of 3 mg/ml of purpurin (Figs. 4A and B). However, in RPMI
medium containing 10% FBS and 3 mg/ml of purpurin, some
fungal cells grew as short pseudohyphae (Fig. 4C), and a higher
concentration (5 mg/ml) of purpurin was required to complete
inhibit filamentation (data not shown).
Cytotoxicity of Purpurin
To evaluate whether purpurin is toxic to human cells, we used
primary HGFs as a surrogate system. Purpurin was non-toxic to
primary HGFs, the viability was 94% at 10 mg/ml as assessed by
the MTT assay (data not shown).
Effect of Purpurin on the Expression of Hypha-specific
Genes and the Hyphal Regulator RAS1
To uncover the underlying relationship between purpurin and
C. albicans morphogenesis, we performed qRT-PCR to assess the
expression of hypha-specific genes and the hyphal regulator RAS1
in C. albicans with purpurin. Purpurin downregulated the
expression of the hypha-specific genes, albeit to various extents
(Fig. 5). In particular, when compared with their respective
untreated controls, the expression of HWP1 was reduced by
.88%; while the transcript levels of ALS3, HYR1 and ECE1 were
lowered by ,59%, ,61%, and ,40% respectively. The
expression of the hyphal regulator RAS1 was reduced by almost
40%.
Figure 2. Scanning electron microscopy images of Candida albicans biofilms. Purpurin exhibited profound inhibitory effect on C. albicans
biofilm formation and pre-formed biofilms. Fungal biofilms were formed on plastic coverslips, processed and coated with gold before viewing with
a scanning electron microscope at low (2006) and high (10006) magnifications. A) Biofilm formation without purpurin. B) Biofilm formation with
3 mg/ml of purpurin. C) Pre-formed biofilms without purpurin. D) Pre-formed biofilms with 3 mg/ml of purpurin.
doi:10.1371/journal.pone.0050866.g002
Figure 3. Effect of purpurin on hyphal formation in Candida albicans. C. albicans was spread on A) Spider agar or B) YPD agar containing 10%
fetal bovine serum in the absence or presence (3 mg/ml) of purpurin. Morphology of fungal colony was photographed after incubation for 4 days at
37uC.
doi:10.1371/journal.pone.0050866.g003
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Discussion
Invasive fungal infections have long been serious problems to
human health, especially to the immunocompromised population.
Despite years of effort, the battle against candidiasis has remained
largely unsuccessful. In view of the limited efficacy of the current
antifungal treatments and the emergence of multidrug resistant
Candida strains, it is in dire need of novel antifungal approaches.
Plant materials have been regarded as ample sources of novel
biomolecules with a broad spectrum of biological and pharmaco-
logical properties. Bioactive compounds with antimicrobial activity
Figure 4. Effect of purpurin on hyphal growth of Candida albicans in liquid media. C. albicans was grown in A) Spider medium or B) YPD
medium containing 10% FBS or C) RPMI medium containing 10% FBS in the absence or presence (3 mg/ml) of purpurin. Samples were withdrawn
after incubation at 37uC for 4 h, and photographed at 1006magnification.
doi:10.1371/journal.pone.0050866.g004
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have been identified [27]; many of them are potent against diverse
fungal pathogens [28].
In an earlier study, our laboratory reported that purpurin
exhibited potent antifungal activity against C. albicans with
a minimum inhibitory concentration of 5.12 mg/ml, and conclud-
ed that the antifungal mechanism of purpurin might involve
perturbation of mitochondrial homeostasis that triggers cellular
apoptosis [20]. In the present study, we extended our investigation
of purpurin on Candida morphogenesis and biofilms using both
qualitative and quantitative methods. SEM was employed as
a qualitative analytical tool to reveal the morphology and
architecture of Candida biofilms at high magnification. The efficacy
of purpurin on Candida biofilms was evaluated quantitatively using
XTT reduction assay. Several methods are available to quantita-
tively assess the viability of C. albicans biofilms, and a recent study
clearly demonstrated that XTT reduction assay provided the most
reproducible and accurate measurement [29]. Inhibition on yeast-
to-hypha transition and biofilms was concentration-dependent.
Three mg/ml of purpurin was sufficient to completely inhibit
filamentation under most hypha-inducing conditions in both solid
and liquid media, except a slightly higher concentration of
purpurin (5 mg/ml) was needed to completely inhibit hyphal
growth in RPMI medium containing 10% FBS. The discrepancy
in the inhibitory effect of purpurin on hyphal growth under
different hypha-inducing conditions might be due to the complex
nature of filamentation in C. albicans in response to environmental
signals, or to other unknown molecular interactions in the
presence of purpurin. A similar phenomenon of medium-de-
pendent inhibition of filamentation in C. albicans was also observed
in the presence of conjugated linoleic acid [30]. Mature biofilms of
C. albicans were less susceptible to purpurin, probably because the
well-established biofilm architecture resists the penetration of
purpurin.
Numerous studies have been performed to identify small
molecules that modulate hyphal formation [31–33]. Hyphae are
integral components in biofilms whose formation has profound
effect on human health and imposes medical challenges. Dentures
and intravenous catheters for medical treatments are substrates for
biofilm development [34]. Formation of biofilms is a step-wise
process. Yeast cells first adhere to the substratum, followed by
initiation of hyphal growth. More extracellular matrix is accumu-
lated in the maturation step and the biofilm structure is formed.
Finally, yeast cells detach and invade surrounding tissues [35].
Respective hypha-specific genes and regulatory pathways have
been identified in different stages of biofilm development. To gain
insight into the effect of purpurin on C. albicans morphogenesis, we
measured the expression of four hypha-specific genes, viz. ALS3,
ECE1, HWP1, HYR1, under hypha-inducing conditions. These
genes encode proteins that are essential for cell wall integrity and
play role in the initiation step of hyphal development. Agglutinin-
like sequence 3 (ALS3) and hyphal wall protein 1 (HWP1) are cell
wall proteins that play key role in intercellular adherence and cell-
substrate interactions for proper formation of three-dimensional
biofilm architecture [36,37]. HYR1 encodes a cell surface
glycosylphosphatidylinositol-anchored protein which confers C.
albicans resistance to phagocyte-mediated killing [38,39], and also
itself a potential target for vaccine development [40]. ECE1 is
essential for cell elongation and biofilm formation [41]. Our data
on transcript analysis showed that their expression was reduced,
and therefore purpurin might exert its antibiofilm effect via
perturbation of cell wall integrity. Hyphal development in C.
albicans is tightly controlled by regulatory circuits that respond to
environmental cues. In RAS1-mediated way, the membrane
localized GTPase Ras1p activates the cAMP-PKA and the
Cek1-MAPK pathways to enhance the levels of Efg1p and Cph1p
respectively for hyphal growth [12]. Expression of the hyphal
regulator RAS1 was downregulated in C. albicans in the presence of
purpurin, implying that purpurin might inhibit the expression of
hypha-specific genes via an RAS1-dependent manner. The
physiological role of RAS1 in C. albicans in response to purpurin
can be assessed by Ras1p overexpression that warrants further
investigation.
C. albicans poses a serious health threat to humans and puts
heavy economic burden on our society. Instead of cell killing,
blocking of virulence traits of pathogens has been recently
considered as a new antifungal paradigm [18]. It is thus
conceivable that suppression of the yeast-to-hypha transition in
C. albicans by purpurin could be a viable antifungal strategy, with
the advantage of a reduced likelihood of acquiring drug resistance
owing to the lower effective concentrations at sub-lethal levels.
In conclusion, the present study demonstrated the in vitro effect
of purpurin on C. albicans hyphal formation and biofilm de-
velopment. Purpurin lowered the expression of RAS1 and hypha-
specific genes in C. albicans. In addition, the non-toxic nature of
purpurin to human cells may have clinical relevance as a new
method to treat candidiasis. Experiments on infection models with
indwelling catheters are being carried out to evaluate the in vivo
application of purpurin.
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